艾伯维获准参与联邦340B返款模式试点，涉及IMBRUVICA、LINZESS和VRAYLAR三款药物
AbbVie to Participate in Federal 340B Rebate Model Pilot
艾伯维获准参与美国HRSA下属OPA的340B返款模式试点项目。自2027年1月1日起，覆盖实体可通过Beacon平台就IMBRUVICA®、LINZESS®和VRAYLAR®三款药物的340B合格配药提交返款申请。艾伯维将免费提供Beacon平台访问及技术支持，并表示该试点有助于提高定价透明度、防止重复折扣。
October 02, 2026
AbbVie to Participate in Federal 340B Rebate Model Pilot
AbbVie has been approved to participate in the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) 340B Rebate Model Pilot Program.
Beginning January 1, 2027, covered entities will submit claims to obtain 340B pricing through Beacon, the technology platform supporting implementation of the rebate model, on 340B-eligible dispenses of three AbbVie medicines: IMBRUVICA®, LINZESS® and VRAYLAR®. AbbVie will provide covered entities with access to Beacon, along with technical assistance, customer service and educational resources, at no cost.
In recognition that organizations may face different operational circumstances, AbbVie will also provide individualized support and consider hardship accommodations to help facilitate a successful transition.
The rebate model pilot is a positive step toward strengthening accountability and addressing longstanding concerns within the 340B program. A well-designed rebate model is an essential tool to enhance program integrity by improving pricing transparency, preventing duplicate discounts and handling complexities introduced by Medicare-negotiated drug prices.
As the pilot is implemented, AbbVie welcomes close collaboration with HRSA, Centers for Medicare and Medicaid Services, covered entities and other key stakeholders to support a successful rollout and evaluate its potential to further strengthen the program.
For more information, click here.
Media:
Adam Mesirow
+1 (708) 879-1191
[email protected]
来源：AbbVie｜艾伯维 · news.abbvie.com